Trial Profile
Diabetes and Combined Lipid Therapy Regimen (DIACOR) Study: A Randomized, Double-Blind Study of Simvastatin, Fenofibrate, and Combined Fenofibrate and Simvastatin in Patients With Controlled Type II Diabetics Without Evidence of Coronary Disease.
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Fenofibrate (Primary) ; Simvastatin (Primary)
- Indications Dyslipidaemias; Lipid metabolism disorders
- Focus Therapeutic Use
- Acronyms DIACOR
- 21 Nov 2006 New trial record.